Managed Account Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Managed Account Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$222M	Buy	1,227,510 +169,272	+16%	+$29.2M	0.18%	146
2015 Q1	$183M	Buy	1,058,238 +174,043	+20%	+$31.5M	0.16%	161
2014 Q4	$164M	Buy	884,195 +129,348	+17%	+$24M	0.16%	160
2014 Q3	$125M	Buy	754,847 +10,369	+1%	+$1.7M	0.14%	179
2014 Q2	$116M	Buy	744,478 +80,328	+12%	+$12.7M	0.14%	178
2014 Q1	$101M	Sell	664,150 -29,395	-4%	-$4.67M	0.13%	187
2013 Q4	$92.2M	Buy	693,545 +21,227	+3%	+$2.55M	0.12%	204
2013 Q3	$78.1M	Sell	672,318 -99,019	-13%	-$10.9M	0.11%	216
2013 Q2	$71.1M	Buy	+771,337	New	+$74.3M	0.11%	219

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Managed Account Advisors's ALXN Position: Q2 2015 in Review

Managed Account Advisors increased its Alexion Pharmaceuticals (ALXN) stake by 16% in Q2 2015, buying an estimated $29.2M and bringing the position to 1,227,510 shares worth $222M. The position accounts for 0.18% of the portfolio, ranked #146.

Managed Account Advisors first reported a position in ALXN in Q2 2013 and has held it in 9 quarters since. 548 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

Managed Account Advisors held 1,227,510 shares of Alexion Pharmaceuticals worth $222M as of Q2 2015.
Managed Account Advisors bought 169,272 Alexion Pharmaceuticals shares in Q2 2015, an estimated $29.2M.
Alexion Pharmaceuticals made up 0.18% of Managed Account Advisors's portfolio in Q2 2015, its #146 holding.
Managed Account Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.